Semorinemab, a monoclonal antibody against phosphorylated tau, failed to significantly alter dementia’s progression in people with early Alzheimer’s disease (AD) taking part in a Phase 2 clinical trial. The investigational therapy, which is being jointly developed by AC Immune and Genentech (a Roche company), also failed to meet secondary trial goals related to cognition and daily living. “Today’s news is surprising and disappointing, given what we as a field know about Tau and its strong…
You must be logged in to read/download the full post.
The post Semorinemab Fails to Show Efficacy in Early Alzheimer’s Phase 2 Trial appeared first on BioNewsFeeds.